Institut Pasteur Korea announced that it will operate ‘cell-based screening technology training’ until September 2nd to spread advanced technologies for new drug development.
Cell-based screening is a cutting-edge technology that precisely analyzes the therapeutic efficacy of research substances in living cells to derive excellent candidates and find clues to the mechanism of action, and is one of the core capabilities of Institut Pasteur Korea.
The training participants were about 20 professors, researchers, and students in the life sciences and medical fields from four countries: Korea, Vietnam, India, and Tunisia, and were selected after a preliminary screening.
Through this process, Institut Pasteur Korea delivers information, knowledge, and know-how to deeply understand and utilize high-speed, high-capacity screening (HCS) technology, and provides a differentiated opportunity to directly perform new drug development screening at each stage of research. Provides training programs.
The detailed program consists of ▲construction and utilization of cell-based research methods (assays) ▲use of cutting-edge automated microscopes ▲small-scale and large-capacity screening ▲screening data analysis. Various meetings for networking among attendees will be held along with topic-specific lectures, experiments, and seminars. do.
In particular, under the guidance of experienced mentors, participants build an assay using actual cells, bacteria, and 3D research models, conduct screening, and then perform a series of processes to analyze the data and derive results, gaining not only related knowledge but also field experience. You can acquire central know-how.
About 20 domestic and foreign experts in the screening field, including Korea and France’s Pasteur Institute, will participate as instructors. Dr. Natalie Olner, head of the photon bioimaging core facility at the Institut Pasteur in France, and Professor Richard Henriques, honorary chair of computational and optical physics at the University of London in the UK, will conduct lectures and seminars online, and will conduct lectures and seminars online, including the Institut Pasteur Korea’s new drug screening platform, technology development platform, and medicinal chemistry. Team leaders and research staff act as dedicated mentors.
Ji Young-mi, director of Institut Pasteur Korea, said, “As a leader in cell-based screening, Institut Pasteur Korea has developed candidate drugs in a short period of time in response to the COVID-19 pandemic, and excellent therapeutic candidates for intractable tuberculosis, hepatitis, antibiotic-resistant bacterial infections, and liver cancer. “By regularly operating flagship training that leverages the institute’s accumulated capabilities, we will widely disseminate screening technology and know-how that can accelerate new drug development, and contribute to nurturing experts and creating a bio-ecosystem.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news